{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:50:17Z","timestamp":1791582617226,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05634-w","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:31:44Z","timestamp":1782534704000},"page":"20105-20116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential efficacy of repurposed drugs for treating drug-resistant visceral leishmaniasis"],"prefix":"10.1007","volume":"399","author":[{"given":"Gajala Deethamvali","family":"Ghousepeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhankar Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailja","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajit","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Priyadarshini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niva","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Samuel","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramendra Pati","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"1","key":"5634_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/AJTMH.16-84256","volume":"96","author":"N Aronson","year":"2017","unstructured":"Aronson N et al (2017) Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 96(1):24. https:\/\/doi.org\/10.4269\/AJTMH.16-84256","journal-title":"Am J Trop Med Hyg"},{"issue":"22","key":"5634_CR2","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.3390\/IJMS20225748","volume":"20","author":"R Capela","year":"2019","unstructured":"Capela R, Moreira R, Lopes F (2019) An overview of drug resistance in protozoal diseases. Int J Mol Sci 20(22):5748. https:\/\/doi.org\/10.3390\/IJMS20225748","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5634_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/S40121-020-00382-7","volume":"10","author":"FB Cavassin","year":"2021","unstructured":"Cavassin FB, Ba\u00fa-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F (2021) Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther 10(1):115. https:\/\/doi.org\/10.1007\/S40121-020-00382-7","journal-title":"Infect Dis Ther"},{"key":"5634_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100317","author":"R Chhajed","year":"2024","unstructured":"Chhajed R et al (2024) Estimating the proportion of relapse following treatment of visceral leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review. Lancet Reg Health Southeast Asia. https:\/\/doi.org\/10.1016\/j.lansea.2023.100317","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"6","key":"5634_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/JAC\/30.6.827","volume":"30","author":"SL Croft","year":"1992","unstructured":"Croft SL, Hogg J, Gutteridge WE, Hudson AT, Randall AW (1992) The activity of hydroxynaphthoquinones against Leishmania donovani. J Antimicrob Chemother 30(6):827\u2013832. https:\/\/doi.org\/10.1093\/JAC\/30.6.827","journal-title":"J Antimicrob Chemother"},{"key":"5634_CR6","unstructured":"Current treatment of leishmaniasis: a review. https:\/\/benthamopen.com\/ABSTRACT\/TOANTIMJ-1-9 (accessed Jun. 18, 2022)."},{"issue":"4","key":"5634_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1017\/S003118201800183X","volume":"146","author":"S De Sarkar","year":"2019","unstructured":"De Sarkar S et al (2019) The leishmanicidal activity of artemisinin is mediated by cleavage of the endoperoxide bridge and mitochondrial dysfunction. Parasitology 146(4):511\u2013520. https:\/\/doi.org\/10.1017\/S003118201800183X","journal-title":"Parasitology"},{"issue":"2","key":"5634_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijpara.2003.10.011","volume":"34","author":"A Debrabant","year":"2004","unstructured":"Debrabant A, Joshi MB, Pimenta PFPP, Dwyer DM (2004) Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int J Parasitol 34(2):205\u2013217. https:\/\/doi.org\/10.1016\/j.ijpara.2003.10.011","journal-title":"Int J Parasitol"},{"issue":"4","key":"5634_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/JAC\/DKM303","volume":"60","author":"T Garnier","year":"2007","unstructured":"Garnier T, M\u00e4ntyl\u00e4 A, J\u00e4rvinen T, Lawrence J, Brown M, Croft S (2007) In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother 60(4):802\u2013810. https:\/\/doi.org\/10.1093\/JAC\/DKM303","journal-title":"J Antimicrob Chemother"},{"key":"5634_CR10","doi-asserted-by":"publisher","DOI":"10.5599\/ADMET.2992","volume":"14","author":"GD Ghousepeer","year":"2026","unstructured":"Ghousepeer GD et al (2026) Insights into drug resistance in Leishmania: mechanisms, therapeutics, and clinical case studies: review paper. ADMET DMPK 14:2992. https:\/\/doi.org\/10.5599\/ADMET.2992","journal-title":"ADMET DMPK"},{"issue":"9185","key":"5634_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","volume":"354","author":"BL Herwaldt","year":"1999","unstructured":"Herwaldt BL (1999) Leishmaniasis. Lancet 354(9185):1191\u20131199. https:\/\/doi.org\/10.1016\/S0140-6736(98)10178-2","journal-title":"Lancet"},{"key":"5634_CR12","unstructured":"ICMR - RM NIHR. https:\/\/www.rmrims.org.in\/mvl.php (accessed May 20, 2026)."},{"key":"5634_CR13","unstructured":"Kala-Azar Situation in India\u202f:: National Center for Vector Borne Diseases Control (NCVBDC). https:\/\/ncvbdc.mohfw.gov.in\/index4.php?lang=1&level=0&linkid=467&lid=3750 (accessed May 20, 2026)."},{"key":"5634_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/J.EJMECH.2018.08.012","volume":"157","author":"S Kapil","year":"2018","unstructured":"Kapil S, Singh PK, Silakari O (2018) An update on small molecule strategies targeting leishmaniasis. Eur J Med Chem 157:339\u2013367. https:\/\/doi.org\/10.1016\/J.EJMECH.2018.08.012","journal-title":"Eur J Med Chem"},{"key":"5634_CR15","doi-asserted-by":"publisher","unstructured":"Kumar R (2024) Epidemiological challenges in India, Handb. Epidemiol\u00a01\u201327\u00a0https:\/\/doi.org\/10.1007\/978-1-4614-6625-3_90-1.","DOI":"10.1007\/978-1-4614-6625-3_90-1"},{"key":"5634_CR16","unstructured":"Leishmaniasis. https:\/\/www.who.int\/health-topics\/leishmaniasis#tab=tab_1 (accessed Jun. 13, 2023)."},{"issue":"1\u20132","key":"5634_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1\u20132):55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4","journal-title":"J Immunol Methods"},{"issue":"1\u20132","key":"5634_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0378-5173(02)00040-6","volume":"237","author":"RH M\u00fcller","year":"2002","unstructured":"M\u00fcller RH, Jacobs C (2002) Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 237(1\u20132):151\u2013161. https:\/\/doi.org\/10.1016\/S0378-5173(02)00040-6","journal-title":"Int J Pharm"},{"key":"5634_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00850-16","author":"D Ortiz","year":"2016","unstructured":"Ortiz D et al (2016) Targeting the cytochrome bc 1 complex of Leishmania parasites for discovery of novel drugs. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00850-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"5634_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/CTM2.552","volume":"11","author":"S Park","year":"2021","unstructured":"Park S et al (2021) Lipid raft\u2010disrupting miltefosine preferentially induces the death of colorectal cancer stem\u2010like cells. Clin Transl Med 11(11):e552. https:\/\/doi.org\/10.1002\/CTM2.552","journal-title":"Clin Transl Med"},{"issue":"5","key":"5634_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.7326\/0003-4819-103-5-782","volume":"103","author":"RD Pearson","year":"1985","unstructured":"Pearson RD, Hewlett EL (1985) Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases. Ann Intern Med 103(5):782\u2013786. https:\/\/doi.org\/10.7326\/0003-4819-103-5-782","journal-title":"Ann Intern Med"},{"issue":"12","key":"5634_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PNTD.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre A et al (2017) Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis 11(12):e0006052. https:\/\/doi.org\/10.1371\/JOURNAL.PNTD.0006052","journal-title":"PLoS Negl Trop Dis"},{"key":"5634_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PNTD.0004093","author":"V Ramesh","year":"2015","unstructured":"Ramesh V et al (2015) Decline in clinical efficacy of oral miltefosine in treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. PLoS Negl Trop Dis. https:\/\/doi.org\/10.1371\/JOURNAL.PNTD.0004093","journal-title":"PLoS Negl Trop Dis"},{"key":"5634_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/J.ACTATROPICA.2024.107143","volume":"252","author":"NRDLP Rossi","year":"2024","unstructured":"Rossi NRDLP et al (2024) Quinine and chloroquine: potential preclinical candidates for the treatment of tegumentary Leishmaniasis. Acta Trop 252:107143. https:\/\/doi.org\/10.1016\/J.ACTATROPICA.2024.107143","journal-title":"Acta Trop"},{"issue":"Pt 9","key":"5634_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1099\/JMM.0.47364-0","volume":"56","author":"R Sen","year":"2007","unstructured":"Sen R et al (2007) Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. J Med Microbiol 56(Pt 9):1213\u20131218. https:\/\/doi.org\/10.1099\/JMM.0.47364-0","journal-title":"J Med Microbiol"},{"issue":"11","key":"5634_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PNTD.0000540","volume":"3","author":"ER Sharlow","year":"2009","unstructured":"Sharlow ER et al (2009) Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3(11):e540. https:\/\/doi.org\/10.1371\/JOURNAL.PNTD.0000540","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"5634_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/S00430-003-0201-2","volume":"193","author":"H Sindermann","year":"2004","unstructured":"Sindermann H et al (2004) Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol 193(4):173\u2013180. https:\/\/doi.org\/10.1007\/S00430-003-0201-2","journal-title":"Med Microbiol Immunol"},{"issue":"2","key":"5634_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/J.EXPPARA.2010.10.014","volume":"127","author":"SK Singh","year":"2011","unstructured":"Singh SK et al (2011) Leishmania donovani: assessment of leishmanicidal effects of herbal extracts obtained from plants in the visceral leishmaniasis endemic area of Bihar, India. Exp Parasitol 127(2):552\u2013558. https:\/\/doi.org\/10.1016\/J.EXPPARA.2010.10.014","journal-title":"Exp Parasitol"},{"issue":"7","key":"5634_CR29","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1021\/ACS.MOLPHARMACEUT.8B00097","volume":"15","author":"L Smith","year":"2018","unstructured":"Smith L, Serrano DR, Mauger M, Bol\u00e1s-Fern\u00e1ndez F, Dea-Ayuela MA, Lalatsa A (2018) Orally bioavailable and effective buparvaquone lipid-based nanomedicines for visceral Leishmaniasis. Mol Pharm 15(7):2570\u20132583. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.8B00097","journal-title":"Mol Pharm"},{"issue":"6","key":"5634_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARCMED.2024.103041","volume":"55","author":"SG Solano-G\u00e1lvez","year":"2024","unstructured":"Solano-G\u00e1lvez SG, Guti\u00e9rrez-Kobeh L, Wilkins-Rodr\u00edguez AA, V\u00e1zquez-L\u00f3pez R (2024) Artemisinin: an anti-leishmania drug that targets the leishmania parasite and activates apoptosis of infected cells. Arch Med Res 55(6):103041. https:\/\/doi.org\/10.1016\/J.ARCMED.2024.103041","journal-title":"Arch Med Res"},{"issue":"16","key":"5634_CR31","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1080\/07391102.2020.1802337","volume":"39","author":"S Yadav","year":"2021","unstructured":"Yadav S, Mandal H, Saravanan V, Das P, Singh SK (2021) In vitro and in silico analysis of L. donovani enoyl acyl carrier protein reductase - a possible drug target. J Biomol Struct Dyn 39(16):6056\u20136069. https:\/\/doi.org\/10.1080\/07391102.2020.1802337","journal-title":"J Biomol Struct Dyn"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05634-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:01:43Z","timestamp":1791579703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05634-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5634"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05634-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}